Farms.com Home   News

Farmers File CWB Case With Supreme Court of Canada

A group of farmer plaintiffs who have filed a Class Action lawsuit in regards to the government's dismantling of the CWB, are asking the Supreme Court of Canada to hear their case.
 
Stewart Wells, chairperson of the Friends of the Canadian Wheat Board says that there are three levels of loss that are being incurred including the values of the ongoing business, the hard assets of the contingency fund, and the misallocation of funds during the transition.
 
Wells notes that together those losses total about a $17 billion loss to western Canadian farmers.
 
"Clearly we believe the brand and the good name of the farmer-owned Wheat Board is also a form of property built and paid for by farmers, and this appeal will allow the Court to address this very substantial loss," he explained.
 
Wells adds that the seizure of the CWB assets and Ottawa's claim that farmers have no rights to them has brought the farm community together to lay claim to all the Wheat Board assets that farmers bought and paid for, and not just the cash remaining in the Pool account.
 

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.